focus -WSS

focus

author：fashion 2025-09-05 13:26:04 - browse：66

Today, if you want to know what scary family health secrets lay buried in your DNA or get screened for a lurking cancer, you have a lot of options. Laboratories have developed more than 75,000 genetic tests, with about 10 new ones entering the market daily. By the end of 2019, more than 26 million Americans had had their DNA decoded to some degree or another. Since then, that number has surely grown.

But this testing frenzy would have been inconceivable just 10 years ago. In part, that’s because the technology back then was so expensive. More importantly, until 2013, it was common practice for gene-hunting academics and companies to lock up their discoveries with DNA patents, effectively carving up the human genome into mini-monopolies. That year, the U.S. Supreme Court threw a bomb into the biotech world when it took up a landmark case that pitted cancer survivors and the American Civil Liberties Union against a diagnostics company called Myriad Genetics, which had obtained exclusive patents on the cancer-causing BRCA genes and made billions of dollars selling tests for them.

A new book called “The Genome Defense,” written by University of Utah science and technology law expert Jorge Contreras and being published Oct. 26, provides a front-row seat to the courtroom drama that would upend three decades of federal intellectual property law and chart a new course toward balancing corporate profits with the rights of all people to the information written into their DNA.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Keeping primary care docs in field isn't impossible, says AAFP CEO

explore

WSS

H.R. 3 is the wrong path to lower drug costs

Carvykti CAR

H.R. 3 is the wrong path to lower drug costs

Keeping primary care docs in field isn't impossible, says AAFP CEO

Medicare drug price negotiation hasn't dried up venture capital

Albert Bourla of Pfizer: worst biopharma CEO of 2023

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Alkermes shareholders re

Medicare slashes safety net hospital payments by nearly $1 billion

Hepatitis C has a cure — but many Americans still lack access to it

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

BioMarin wins approval for gene therapy to treat hemophilia A

Group behind ProMed defends move to subscription

George Santos makes 1st court appearance after pleading not guilty to 13 counts

HCA sued by state AG for quality issues at Mission Health

Medicare proposal to cover medical devices draws a mixed reaction

Florida officials tell state schools to teach AP Psychology 'in its entirety'

leisure time

Can sheer will power keep patients alive in their dying hours?

Late stage cancers on the rise after pandemic delayed screenings

Late stage cancers on the rise after pandemic delayed screenings

Christmas in the PICU brings some surprising joy

A controversial new treatment promises to make little people taller

Bristol Myers buys into radiopharmaceuticals with RayzeBio

explore

entertainment

explore

Wikipedia